Merck & Co., Inc. vs Teucrium Soybean Fund — how do they compare? Merck & Co., Inc. trades at $148.1 (market cap $366.28B), while Teucrium Soybean Fund trades at $27.66. The key difference: Merck & Co., Inc. pays a 2.29% dividend while Teucrium Soybean Fund pays none. Which is the better fit depends on your goals.
| MRK | SOYB | |
|---|---|---|
Market Cap | $366.28B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $156.43 | $27.84 |
52-Week Low | $77.60 | $21.46 |
Enterprise Value | $413.04B | — |
Dividend Yield | 2.29% | — |
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $156.71. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending, and maintains a robust gross profit margin of 72.97%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.
The outlook for MRK is positive, driven by earnings momentum and strategic acquisitions, but risks include high valuation multiples like a P/E of 118.77 and regulatory pressures. Investors should weigh the company's solid cash flow and analyst support against potential market volatility and integration challenges from recent M&A activity.
SOYB trades at $27.84, up 0.69% today, with a bullish technical signal from moving averages but bearish oscillators. The stock shows strong momentum indicators, with RSI levels indicating overbought conditions. Recent news highlights commodity price trends influencing agricultural stocks.
The outlook remains tied to commodity market dynamics, with potential upside from rising soybean prices but risks from geopolitical tensions and volatility. Investors should weigh technical overbought signals against fundamental growth catalysts in the agricultural sector.
Trailing returns across standard periods
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →SOYB is a commodity ETF that provides exposure to the price of soybean futures. It utilizes a laddered strategy by investing in several benchmark futures contracts to reduce the impact of roll costs and contango in the agricultural market.
Read more on SOYB →